EOLS
Price
$7.66
Change
+$0.15 (+2.00%)
Updated
Sep 5 closing price
Capitalization
495.49M
64 days until earnings call
SGIOY
Price
$8.99
Change
+$0.26 (+2.98%)
Updated
Sep 5 closing price
Capitalization
15.28B
49 days until earnings call
Interact to see
Advertisement

EOLS vs SGIOY

Header iconEOLS vs SGIOY Comparison
Open Charts EOLS vs SGIOYBanner chart's image
Evolus
Price$7.66
Change+$0.15 (+2.00%)
Volume$535K
Capitalization495.49M
Shionogi & Co
Price$8.99
Change+$0.26 (+2.98%)
Volume$84.38K
Capitalization15.28B
EOLS vs SGIOY Comparison Chart in %
Loading...
EOLS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SGIOY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
EOLS vs. SGIOY commentary
Sep 08, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EOLS is a Hold and SGIOY is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 08, 2025
Stock price -- (EOLS: $7.66 vs. SGIOY: $8.99)
Brand notoriety: EOLS and SGIOY are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: EOLS: 37% vs. SGIOY: 101%
Market capitalization -- EOLS: $495.49M vs. SGIOY: $15.28B
EOLS [@Pharmaceuticals: Generic] is valued at $495.49M. SGIOY’s [@Pharmaceuticals: Generic] market capitalization is $15.28B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $67.95B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.93B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

EOLS’s FA Score shows that 0 FA rating(s) are green whileSGIOY’s FA Score has 2 green FA rating(s).

  • EOLS’s FA Score: 0 green, 5 red.
  • SGIOY’s FA Score: 2 green, 3 red.
According to our system of comparison, SGIOY is a better buy in the long-term than EOLS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

EOLS’s TA Score shows that 5 TA indicator(s) are bullish while SGIOY’s TA Score has 5 bullish TA indicator(s).

  • EOLS’s TA Score: 5 bullish, 2 bearish.
  • SGIOY’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, EOLS is a better buy in the short-term than SGIOY.

Price Growth

EOLS (@Pharmaceuticals: Generic) experienced а +0.39% price change this week, while SGIOY (@Pharmaceuticals: Generic) price change was +4.41% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +0.08%. For the same industry, the average monthly price growth was +12.00%, and the average quarterly price growth was +86.48%.

Reported Earning Dates

EOLS is expected to report earnings on Nov 11, 2025.

SGIOY is expected to report earnings on Oct 27, 2025.

Industries' Descriptions

@Pharmaceuticals: Generic (+0.08% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SGIOY($15.3B) has a higher market cap than EOLS($495M). SGIOY YTD gains are higher at: 29.169 vs. EOLS (-30.616). SGIOY has higher annual earnings (EBITDA): 206B vs. EOLS (-33.58M). SGIOY has more cash in the bank: 576B vs. EOLS (61.7M). EOLS has less debt than SGIOY: EOLS (155M) vs SGIOY (11.7B). SGIOY has higher revenues than EOLS: SGIOY (419B) vs EOLS (278M).
EOLSSGIOYEOLS / SGIOY
Capitalization495M15.3B3%
EBITDA-33.58M206B-0%
Gain YTD-30.61629.169-105%
P/E RatioN/A13.29-
Revenue278M419B0%
Total Cash61.7M576B0%
Total Debt155M11.7B1%
FUNDAMENTALS RATINGS
EOLS vs SGIOY: Fundamental Ratings
EOLS
SGIOY
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
92
Overvalued
22
Undervalued
PROFIT vs RISK RATING
1..100
7391
SMR RATING
1..100
1002
PRICE GROWTH RATING
1..100
6450
P/E GROWTH RATING
1..100
10044
SEASONALITY SCORE
1..100
1075

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

SGIOY's Valuation (22) in the null industry is significantly better than the same rating for EOLS (92) in the Pharmaceuticals Major industry. This means that SGIOY’s stock grew significantly faster than EOLS’s over the last 12 months.

EOLS's Profit vs Risk Rating (73) in the Pharmaceuticals Major industry is in the same range as SGIOY (91) in the null industry. This means that EOLS’s stock grew similarly to SGIOY’s over the last 12 months.

SGIOY's SMR Rating (2) in the null industry is significantly better than the same rating for EOLS (100) in the Pharmaceuticals Major industry. This means that SGIOY’s stock grew significantly faster than EOLS’s over the last 12 months.

SGIOY's Price Growth Rating (50) in the null industry is in the same range as EOLS (64) in the Pharmaceuticals Major industry. This means that SGIOY’s stock grew similarly to EOLS’s over the last 12 months.

SGIOY's P/E Growth Rating (44) in the null industry is somewhat better than the same rating for EOLS (100) in the Pharmaceuticals Major industry. This means that SGIOY’s stock grew somewhat faster than EOLS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
EOLSSGIOY
RSI
ODDS (%)
Bullish Trend 4 days ago
83%
Bearish Trend 4 days ago
50%
Stochastic
ODDS (%)
Bearish Trend 4 days ago
75%
Bullish Trend 4 days ago
63%
Momentum
ODDS (%)
Bullish Trend 4 days ago
78%
Bullish Trend 4 days ago
68%
MACD
ODDS (%)
Bullish Trend 4 days ago
74%
Bearish Trend 4 days ago
54%
TrendWeek
ODDS (%)
Bullish Trend 4 days ago
79%
Bullish Trend 4 days ago
62%
TrendMonth
ODDS (%)
Bearish Trend 4 days ago
82%
Bullish Trend 4 days ago
68%
Advances
ODDS (%)
Bullish Trend 4 days ago
79%
Bullish Trend 12 days ago
65%
Declines
ODDS (%)
Bearish Trend 6 days ago
81%
Bearish Trend 7 days ago
58%
BollingerBands
ODDS (%)
Bullish Trend 4 days ago
88%
Bearish Trend 4 days ago
63%
Aroon
ODDS (%)
N/A
Bullish Trend 4 days ago
78%
View a ticker or compare two or three
Interact to see
Advertisement
EOLS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SGIOY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
SROCX13.410.02
+0.15%
Calamos Antetokounmpo Sustainable Eqs C
ASQGX17.860.02
+0.11%
American Century Small Company R5
CSECX34.28-0.07
-0.20%
Calvert Equity C
MSOAX39.79-0.11
-0.28%
NYLI WMC Enduring Capital Class A
FGIPX16.71-0.07
-0.42%
Macquarie Growth and Income Instl

EOLS and

Correlation & Price change

A.I.dvisor indicates that over the last year, EOLS has been loosely correlated with PRGO. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if EOLS jumps, then PRGO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EOLS
1D Price
Change %
EOLS100%
+2.00%
PRGO - EOLS
43%
Loosely correlated
-2.75%
AMRX - EOLS
33%
Poorly correlated
+0.73%
LNTH - EOLS
32%
Poorly correlated
+1.73%
ALKS - EOLS
30%
Poorly correlated
+3.53%
CRDL - EOLS
30%
Poorly correlated
-1.80%
More

SGIOY and

Correlation & Price change

A.I.dvisor tells us that SGIOY and ANIP have been poorly correlated (+22% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that SGIOY and ANIP's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SGIOY
1D Price
Change %
SGIOY100%
+2.98%
ANIP - SGIOY
22%
Poorly correlated
-0.68%
EOLS - SGIOY
21%
Poorly correlated
+2.00%
TAK - SGIOY
20%
Poorly correlated
+0.72%
TKPHF - SGIOY
9%
Poorly correlated
+11.86%
ROMJF - SGIOY
8%
Poorly correlated
-4.79%
More